67812-42-4

基本信息
盐酸去甲维拉帕米
去甲维拉帕米盐酸盐
盐酸去甲维拉帕米(N-去甲 盐酸维拉帕米)
NORVERAPAMIL HYDROCHLORIDE
n-nor-(±)-verapamil hydrochloride
(±)-Norverapamill hydrochloride solution
(+/-)-VERAPAMIL, NOR-METHYL-, HYDROCHLORIDE
NorverapaMil HCl (N-DesMethyl VerapaMil HCl)
(+-)-VERAPAMIL HYDROCHLORIDE, NOR-METHYL (NORVERAPAMIL HYDROCH
a-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-a-(1-methylethyl)-benzeneacetonitril
a-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-a-(1-methylethyl)-benzeneacetonitrile
α-[3-[[2-(3,4-Dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-α-(1-methylethyl)- benzeneacetonitrile
物理化学性质
熔点 | softens at 50°C, 155-160°C dec. |
闪点 | 9℃ |
储存条件 | -20°C Freezer, Under Inert Atmosphere |
溶解度 | H2O: >10 mg/mL |
形态 | solid |
颜色 | white |
水溶解性 | H2O: 15mg/mL, clear |
稳定性 | 吸湿性 |
EPA化学物质信息 | Benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-, hydrochloride (1:1) (67812-42-4) |
安全数据
危险性符号(GHS) | ![]() GHS07 |
警示词 | 警告 |
危险性描述 | H302-H315-H319-H335 |
防范说明 | P261-P264-P270-P301+P312-P302+P352-P305+P351+P338 |
危险品运输编号 | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
盐酸去甲维拉帕米价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/02/08 | HY-100750 | 盐酸去甲维拉帕米 Norverapamil hydrochloride | 67812-42-4 | 1 mg | 400元 |
2025/02/08 | HY-100750 | 盐酸去甲维拉帕米 Norverapamil hydrochloride | 67812-42-4 | 5mg | 1400元 |
2025/02/08 | HY-100750 | 盐酸去甲维拉帕米 Norverapamil hydrochloride | 67812-42-4 | 10mM * 1mLin DMSO | 1470元 |
常见问题列表
Calcium channel blocker
P-glycoprotein (P-gp) inhibitor
Norverapamil hydrochloride ((±)-Norverapamil hydrochloride) is similarly effective as verapamil at inhibiting isoniazid and rifampicin tolerance and killing of intracellular M. tuberculosis in the absence of other drugs. norverapamil, also inhibits macrophage-induced tolerance and achieves similar serum levels to verapamil.
Verapamil and its major metabolite norverapamil were identified to be both mechanism-based inhibitors and substrates of CYP3A and reported to have non-linear pharmacokinetics in clinic.
Norverapamil hydrochloride (9 mg/kg; p.o.), a major metabolite of verapamil, has terminal half-life, AUC and Cmax values of 9.4 hours, 260 ng▪h/ml, and 41.6 ng/mL, respectively.
Animal Model: | Male Sprague-Dawley rats |
Dosage: | 9 mg/kg (Pharmacokinetic Study) |
Administration: | Oral administration |
Result: | t 1/2 =9.4 hours; AUC=260 ng▪h/mL; C max =41.6 ng/mL. |